Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
TBPH Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TBPH Stock 12 Month Forecast
Average Price Target
$28.40
▲(51.14% Upside)
| Highest Price Target$42.00 | Average Price Target$28.40 | Lowest Price Target$13.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$40
Buy
112.88%
Upside
Reiterated
12/09/25
H.C. Wainwright
$20
Buy
6.44%
Upside
Reiterated
12/09/25
Theravance Biopharma's Ampreloxetine: A Promising Treatment for Neurogenic Orthostatic Hypotension with Strong Commercial ProspectsValuation and Risks. Our Buy rating and price target of $20 are based on 4x our discounted 2035 risk-adjusted revenue estimate of $316M. We adjust each pipeline asset for the probability of success (PoS). Commercial asset, Yupelri revenues are assigned a PoS of 100%. We assign a for ampretoxetine as a Phase 3 asset. Key risks include clinical development on key pipeline assets, especially ampreloxetine and commercial on execution of Yupelri.
JonesTrading
$42
Buy
123.52%
Upside
Reiterated
12/09/25
Oppenheimer
$27
Buy
43.69%
Upside
Initiated
12/03/25
TD Cowen
$13
Hold
-30.81%
Downside
Reiterated
11/11/25
Theravance Biopharma: Hold Rating Amid Steady Growth and Pipeline UncertaintyWe remain at Hold. Viatris reported net Yupelri sales of $71.4MM in +15% Y/Y). This led Theravance to record collaboration revenue of $20MM (+7% Q/Q, +18% Y/Y) matching consensus. Management reported that Yupelri's performance was driven by steady growth in patient demand (+6% in hospital channel) as well as continued improvements in channel mix. Hospital volume continues to be a driver of new prescriptions as the majority of patients receive a script at discharge. We note the general Q/Q trend of increasing margins for Yupelri has lead to non-GAAP breakeven in Q3. Management reiterated it's commitment to increasing operating leverage and cost discipline ahead of ampreloxetine Ph3 data in 2026. Management expects steady to incrementally improving margins in 2026.
B. Riley Securities
$28
Buy
49.02%
Upside
Initiated
09/12/25
Leerink Partners
$10→$13
Hold
-30.81%
Downside
Reiterated
08/13/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$40
Buy
112.88%
Upside
Reiterated
12/09/25
H.C. Wainwright
$20
Buy
6.44%
Upside
Reiterated
12/09/25
Theravance Biopharma's Ampreloxetine: A Promising Treatment for Neurogenic Orthostatic Hypotension with Strong Commercial ProspectsValuation and Risks. Our Buy rating and price target of $20 are based on 4x our discounted 2035 risk-adjusted revenue estimate of $316M. We adjust each pipeline asset for the probability of success (PoS). Commercial asset, Yupelri revenues are assigned a PoS of 100%. We assign a for ampretoxetine as a Phase 3 asset. Key risks include clinical development on key pipeline assets, especially ampreloxetine and commercial on execution of Yupelri.
JonesTrading
$42
Buy
123.52%
Upside
Reiterated
12/09/25
Oppenheimer
$27
Buy
43.69%
Upside
Initiated
12/03/25
TD Cowen
$13
Hold
-30.81%
Downside
Reiterated
11/11/25
Theravance Biopharma: Hold Rating Amid Steady Growth and Pipeline UncertaintyWe remain at Hold. Viatris reported net Yupelri sales of $71.4MM in +15% Y/Y). This led Theravance to record collaboration revenue of $20MM (+7% Q/Q, +18% Y/Y) matching consensus. Management reported that Yupelri's performance was driven by steady growth in patient demand (+6% in hospital channel) as well as continued improvements in channel mix. Hospital volume continues to be a driver of new prescriptions as the majority of patients receive a script at discharge. We note the general Q/Q trend of increasing margins for Yupelri has lead to non-GAAP breakeven in Q3. Management reiterated it's commitment to increasing operating leverage and cost discipline ahead of ampreloxetine Ph3 data in 2026. Management expects steady to incrementally improving margins in 2026.
B. Riley Securities
$28
Buy
49.02%
Upside
Initiated
09/12/25
Leerink Partners
$10→$13
Hold
-30.81%
Downside
Reiterated
08/13/25
Best Analysts Covering Theravance Biopharma
1 Month
xxx
Success Rate
10/16 ratings generated profit
Average Return
+0.91%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +0.91% per trade.
3 Months
xxx
Success Rate
9/16 ratings generated profit
Average Return
+4.77%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +4.77% per trade.
1 Year
Success Rate
4/7 ratings generated profit
Average Return
+25.20%
reiterated a buy rating 12 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +25.20% per trade.
2 Years
xxx
Success Rate
13/16 ratings generated profit
Average Return
+56.83%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +56.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TBPH Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
7
12
10
8
6
Buy
0
1
2
3
4
Hold
12
15
10
11
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
28
22
22
17
Each month's total comprises the sum of three months' worth of ratings.
TBPH Financial Forecast
TBPH Stock Forecast FAQ
What is TBPH’s average 12-month price target, according to analysts?
Based on analyst ratings, Theravance Biopharma’s 12-month average price target is 28.40.
What is TBPH’s upside potential, based on the analysts’ average price target?
Theravance Biopharma has 51.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TBPH a Buy, Sell or Hold?
Theravance Biopharma has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Theravance Biopharma’s price target?
The average price target for Theravance Biopharma is 28.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $42.00 ,the lowest forecast is $13.00. The average price target represents 51.14% Increase from the current price of $18.79.
The highest analyst price target is $42.00 ,the lowest forecast is $13.00. The average price target represents 51.14% Increase from the current price of $18.79.
What do analysts say about Theravance Biopharma?
Theravance Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of TBPH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.